Risk Mitigation Through Dual Sourcing Strategy

A global biopharmaceutical company with a high value, highly potent drug product for a rare disease indication approached PCI as part of an internal strategy to secure the supply of one of their life-changing commercial drug products. The client company had classified this drug product as being a critical therapy within their portfolio and in order to comply with their internal policy, required a dual sourcing strategy to ensure absolute supply chain security for their patients. The internal policy also required a full service solution for both commercial manufacturing and packaging that would guarantee supply and provide flexibility to deliver a comprehensive risk mitigation strategy.